BioSpace News Archive

Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.

Strata Oncology, Inc., today announced enrollment of the first patient in the Strata Sentinel™ trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD™ test to detect cancer recurrence in advance of standard of care techniques across solid tumors.

Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK.

KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of financing.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), announced today the first in-human experience with Propel™, its first-generation percutaneous ventricular assist device (pVAD), offering hemodynamic support for patients undergoing high-risk percutaneous coronary interventions (HR-PCI).

KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and development of leading-edge oncolytic vaccinia virus immunotherapies, announced the closing of its Series A financing.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022.

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, opened its new facility in Newark, California, where it will relocate its corporate headquarters this year.

According to Report, the cancer immunotherapy market is expected to grow at a notable CAGR of 12.6% over forecast period 2021 to 2030 and to reach over US$ 277.1 billion by 2030.